External broker reports(aggregated public sources), CMB International

CMB International

External broker reports(aggregated public sources)

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

Equity Bottom-Up

<ul><li>A landmark step of globalization with fruquintinib’s FDA approval.</li><li>HCM’s partner Takeda received FDA approval for fruquintinib for the treatment of mCRC patients who were previously treated with chemo therapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy.</li><li>The approval was received under Priority Review more 20 days ahead of the scheduled PDUFA date of 30th Nov. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

A landmark step of globalization with fruquintinib’s FDA approval.HCM’s partner Takeda received FDA approval for fruquintinib for the treatment of mCRC patients who were previously treated with chemo therapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy.The approval was received under Priority Review more 20 days ahead of the scheduled PDUFA date of 30th Nov. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Hutchmed (13 HK) – Big Milestone Achieved with Fruquintinib Successfully Approved by US FDA

<ul><li>HCM’s consolidated revenues from oncology/immunology increased 294% YoY to US$359mn in 1H23, mainly driven by the US$259mn income recognition related to the total US$400mn upfront payment received from Takeda.</li><li>The in-market product sales increased 16% YoY (25% at CER) to US$101mn in 1H23, among which sales of fruquintinib increased 12% YoY (20% at CER) to US$56mn, maintaining leadership in patient share (47%) in 3L CRC in China.</li><li>Surufatinib’s in-market sales in 1H23 increased 66% YoY (79% at CER) to US$23mn, driven by increase in DoT and additional hospital listings. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

HCM’s consolidated revenues from oncology/immunology increased 294% YoY to US$359mn in 1H23, mainly driven by the US$259mn income recognition related to the total US$400mn upfront payment received from Takeda.The in-market product sales increased 16% YoY (25% at CER) to US$101mn in 1H23, among which sales of fruquintinib increased 12% YoY (20% at CER) to US$56mn, maintaining leadership in patient share (47%) in 3L CRC in China.Surufatinib’s in-market sales in 1H23 increased 66% YoY (79% at CER) to US$23mn, driven by increase in DoT and additional hospital listings. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Hutchmed (13 HK) – Eyes on the FDA Approval of Fruquintinib in Nov

<ul><li>HCM continued to prove its strong commercial capabilities by achieving remarkable 63% YoY growth in oncology product sales in FY22, reaching US$124.6mn, driven by its three commercial drugs.</li><li>HCM targets to grow the oncology product sales by high double-digit in FY23 while the management expects US$450-550mn consolidated oncology revenue in FY23, including partial recognition of US$400mn upfront payment from Takeda.</li><li>The R&amp;D expenses in FY22 were US$386.9mn (+29% YoY). As of end-2022, HCM had a strong cash position of US$631.0mn. The Company targets to turn profitable in 2025.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

HCM continued to prove its strong commercial capabilities by achieving remarkable 63% YoY growth in oncology product sales in FY22, reaching US$124.6mn, driven by its three commercial drugs.HCM targets to grow the oncology product sales by high double-digit in FY23 while the management expects US$450-550mn consolidated oncology revenue in FY23, including partial recognition of US$400mn upfront payment from Takeda.The R&amp;D expenses in FY22 were US$386.9mn (+29% YoY). As of end-2022, HCM had a strong cash position of US$631.0mn. The Company targets to turn profitable in 2025.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Hutchmed (13 HK) – Exploit global market opportunities

<div><div><div><div><ul><li>Superior improvement in overall survival in mCRC. HCM released data of the global Ph3 FRESCO-2 trial of fruquintinib in refractory metastatic colorectal cancer (CRC) at ESMO 2022 (link).</li><li>The study enrolled 691 heavily pre-treated mCRC patients globally (71% from Europe, 18% from the US, 8% from Japan and 3% from AU).</li><li>The median line of prior treatments was five, and 91% and 48% of patients had previously received TAS-102 and regorafenib, respectively. </li></ul></div></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Superior improvement in overall survival in mCRC. HCM released data of the global Ph3 FRESCO-2 trial of fruquintinib in refractory metastatic colorectal cancer (CRC) at ESMO 2022 (link).The study enrolled 691 heavily pre-treated mCRC patients globally (71% from Europe, 18% from the US, 8% from Japan and 3% from AU).The median line of prior treatments was five, and 91% and 48% of patients had previously received TAS-102 and regorafenib, respectively. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Hutchmed (13 HK) – Fruquintinib to unlock the global potential in mCRC indication

Hong Kong

HUTCHMED (China) Limited develops, manufactures, and sells pharmaceutical products. The Company offers drugs for oncology and autoimmune diseases treatment. HUTCHMED (China) markets its products worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Hutchmed China Ltd (13 HK)

Hutchmed (13 HK) – Big Milestone Achieved with Fruquintinib Successfully Approved by US FDA

The approval was based on the Ph3 MRCT FRESCO-2 (18% patients enrolled from the US) as well as the China FRESCO trial, implying the recognition of...

CMB International

Hutchmed (13 HK) – Eyes on the FDA Approval of Fruquintinib in Nov

HCM’s consolidated revenues from oncology/immunology increased 294% YoY to US$359mn in 1H23, mainly driven by the US$259mn income recognition

CMB International

Hutchmed (13 HK) – Exploit global market opportunities

HCM continued to prove its strong commercial capabilities by achieving remarkable 63% YoY growth in oncology product sales in FY22, reaching...

CMB International

Hutchmed (13 HK) – Fruquintinib to unlock the global potential in mCRC indication

The median line of prior treatments was five, and 91% and 48% of patients had previously received TAS-102 and regorafenib, respectively.

CMB International

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)